Epidiolex

GW Pharmaceuticals plc (NASDAQ: GWPH) reported financial results for its fiscal fourth quarter 2018. Compared to analysts' consensus estimates, the company reported a better-than-expected net loss, but its top line missed the expectations. What Happened For the quarter ended Sept. 30, GW...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) announced incremental positive news on its lead cannabinoid product candidate Epidiolex, sending the stock higher. What Happened GW Pharma announcedpositive results for a second, late-stage study that evaluated its Epidiolex oral solution for treatment...

Leerink is taking a bullish stance on GW Pharmaceuticals PLC (ADR) (NASDAQ: GWPH), with a thesis centering around the company's lead drug Epidiolex; the drug Sativex; GW's involvement in the epilepsy market and its cannabinoid science platform. The Analyst Leerink's Marc Goodman...

By Sunday night, the U.S. Drug Enforcement Administration is expected to reclassify GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)’s Epidiolex to allow medicinal use. This could open the therapy to a new and promising market. The Analyst  Morgan Stanley analyst David Lebowitz ...

After a huge year in 2017, GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) stock has traded mostly sideways so far in 2018. But one analysts believes GW will soon return to its winning ways. The Analyst Stifel analyst Paul Matteis initiated coverage of GW Pharma with a Buy rating and $181 price target....

The U.S. Food and Drug Administration approval of GW Pharmaceuticals PLC (NASDAQ: GWPH)'s epidiolex therapy for the treatment of seizures was expected — and reinforces the bullish case for owning the stock, according to Bank of America Merrill Lynch.  The Analyst Bank of America'...

The month of May saw several drugs passing the FDA muster, with new molecular entity approvals alone totaling five. NMEs are those innovative new products containing active moieties that haven't been approved by the agency previously, either as a single ingredient drug, or as part of a...

Shares of cannabinoid-focused biotech company GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) are "on a path to new highs," according to Goldman Sachs. The Analyst Goldman Sachs analyst Salveen Richter upgraded GW Pharma from Neutral to Buy and lifted her price target to $174, suggesting...

The month of August has been hard one for cannabis drug stocks. After Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) reported a pair of disappointing trial results in its Phase 2 STAR 1 and STOP trials, respectively, the company’s market cap went up in smoke to the tune of a more than 50 percent...

Elemer Piros of Cantor Fitzgerald maintained an Overweight rating and $208 price target on GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) after the developer of cannbinoid products reported its fiscal second-quarter results. Piros' main takeaway from the report and conference call is that GW...

Leerink's Global Healthcare Conference kicked off Wednesday and will continue through Thursday. Here is a summary of what Leerink's analysts are saying about some of the notable companies who presented at on Wednesday. Universal Health Services Universal Health Services, Inc. (NYSE: UHS)'s chief...

Being a one-trick pony can always prove risky. This rationale seems to have dawned on GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH), a biopharmaceutical company specializing in prescription cannabinoid medicine. Risk Mitigation Through Diversification The company announced Tuesday positive top...

Cantor Fitzgerald has raised its price target on GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) to $208/ADS from $182/ADS after additional positive Epidiolex results. Epidiolex Significance The recent data of Epidiolex presented at the American Epilepsy Society (AES) event showed “robustness and...

Cannabinoid drug developer GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) is ending an eventful 2016 on a high note. Shares were surging higher by 6.6 percent on Monday following new drug data out over the weekend and a strong fiscal Q4 earnings report out Monday. Over the weekend, the company reported...

Over the weekend, GW Pharmaceuticals PLC – ADR (NASDAQ: GWPH) presented additional data from its Phase III trials of Epidiolex in Lennox-Gastaut (LGS) and Dravet syndromes, at the American Epilepsy Society (AES) meeting. Cantor Fitzgerald’s Elemer Piros maintained a Buy rating on...